HCC 10+ Years After Viral Eradication in Patients With HCV HCC 10+ Years After Viral Eradication in Patients With HCV
What risk factors are associated with hepatocellular carcinoma development 10 years or more after SVR?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 7, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Liver Cancer Risk May Rise for 2nd - , 3rd - Generation U.S. Mexicans
Risk of hepatocellular carcinoma increased by 35 and 61 percent for second - , third - versus first - generation U.S. Mexicans (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 20, 2022 Category: Cancer & Oncology Tags: Gastroenterology, Internal Medicine, Oncology, Conference News, Source Type: news
Liver Cancer Risk May Rise for 2nd-, 3rd-Generation U.S. Mexicans
TUESDAY, Sept. 20, 2022 -- The risk of hepatocellular carcinoma (HCC) appears to be increased for successive generations of U.S. Mexicans, according to a study presented at the 15th AACR Conference on the Science of Cancer Health Disparities in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2022 Category: Pharmaceuticals Source Type: news
NAFLD Fibrosis Scores Predict Liver-related HCV Complications NAFLD Fibrosis Scores Predict Liver-related HCV Complications
This study evaluated the use of noninvasive fibrosis assessments for predicting liver-related complications and hepatocellular carcinoma occurrence in patients with chronic HCV receiving DAA therapy.Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 20, 2022 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news
Novel Blood Test for Early-Stage Liver Cancer Shows Promise Novel Blood Test for Early-Stage Liver Cancer Shows Promise
The blood test identifies early-stage hepatocellular carcinoma in patients at risk with around 90% accuracy and could augment current surveillance methods and improve patient outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 8, 2022 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news
SGLT2 Inhibitors Lower NAFLD, HCC Risks Over DPP4i SGLT2 Inhibitors Lower NAFLD, HCC Risks Over DPP4i
Sodium glucose cotransporter 2 inhibitors (SGLT2is) lowered the risk of nonalcoholic fatty liver disease and hapatocellular carcinoma versus dipeptidyl-peptidase-4 inhibitors (DPP4is).First Look (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 1, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Intermediate-Stage HCC Treatment in the Era of Immunotherapy Intermediate-Stage HCC Treatment in the Era of Immunotherapy
Learn more about the therapeutic advances that have redefined the treatment possibilities for intermediate-stage hepatocellular carcinoma.Journal of Oncology Practice (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 1, 2022 Category: Surgery Tags: Hematology-Oncology Journal Article Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Outcome of Liver Cancer Patients With SARS-CoV-2 Infection Outcome of Liver Cancer Patients With SARS-CoV-2 Infection
This study characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with hepatocellular carcinoma.Liver International (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - August 23, 2022 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news
Pervasive'Forever Chemical' Linked to Liver Cancer Pervasive'Forever Chemical' Linked to Liver Cancer
Exposure to perfluorooctane sulfonic acid correlates with an elevated risk for hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 23, 2022 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news
Machine learning improves MRI's ability to predict liver cancer return
Using machine learning with MRI data appears to help predict liver cancer recurrenc...Read more on AuntMinnie.comRelated Reading:
CEUS-guided biopsy shows superiority in liver imaging
Ultrasonic subthreshold observations unlikely to become HCC
CT radiomics helps predict HCC recurrence after liver transplant
Algorithm helps monitor HCC treatment response
AI can identify hepatocellular carcinoma on liver CT exams (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 22, 2022 Category: Radiology Source Type: news
Mesothelioma Clinical Trial Studies Keytruda, Lenvatinib Combination
The objective response rate of the Keytruda/lenvatinib combination was an impressive 58%.
In 2020, the U.S. Food and Drug Administration approved the use of Keytruda for certain metastatic tumors, including certain cases of mesothelioma, but the search for an effective combination continues.
Lenvatinib has shown it can block tumor growth by targeting specific proteins Keytruda can’t reach. It has been effective with only select cancers and is known as precision medicine.
The drug, which is already FDA approved, has been used successfully with Keytruda for the treatment of endometrial cancer. Lenvatinib is prescr...
Source: Asbestos and Mesothelioma News - August 17, 2022 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Pleural Source Type: news
Neighborhood Factors Contribute to Liver Cancer Disparities Neighborhood Factors Contribute to Liver Cancer Disparities
Texas has the highest rate of hepatocellular carcinoma in the United States, and new research sheds light on why incidence rates vary across the state by race, ethnicity, and geographic location.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 10, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Treatment Combo Shows'Clinical Benefit' in Liver Cancer Trial Treatment Combo Shows'Clinical Benefit' in Liver Cancer Trial
The combination of a tyrosine kinase inhibitor with an immune checkpoint inhibitor significantly improved progression-free survival in patients with hepatocellular carcinoma, shows a new study.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 5, 2022 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
Adding TACE to Lenvatinib Boosts Survival in Advanced Liver Cancer
(MedPage Today) -- Combining transarterial chemoembolization (TACE) with lenvatinib (Lenvima) as first-line treatment for advanced hepatocellular carcinoma (HCC) prolonged survival compared with lenvatinib alone, the phase III LAUNCH trial showed... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 4, 2022 Category: Gastroenterology Source Type: news
